The combination of an Ang/Tie‐2 inhibitor (trebananib) targeting Ang‐1, Ang‐2, and Tie‐2 receptors with a VEGF inhibitor was expected to have an effective anti‐tumor effect on glioblastoma but did not show a prognostic benefit in a clinical trial (NCT01609790) [49]. Here, TEK is linked to neoplasm.